Analysis of Spontaneously Reported Adverse Events
نویسندگان
چکیده
منابع مشابه
Spontaneously Reported Hepatic Adverse Drug Events in Korea: Multicenter Study
Hepatic adverse drug reactions (ADRs) to certain drugs may differ within each country, reflecting different patterns of prescription, socioeconomic status, and culture. The purpose of this study was to assess the suspected cause of hepatic ADRs using the spontaneously reported pharmacovigilance data from Korea. A total of 9,360 spontaneously reported adverse drug events (ADEs) from nine Pharmac...
متن کاملRelating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales
BACKGROUND While antipsychotic-induced extrapyramidal symptoms (EPS) and akathisia remain important concerns in the treatment of patients with schizophrenia, the relationship between movement disorder rating scales and spontaneously reported EPS-related adverse events (EPS-AEs) remains unexplored. METHODS Data from four randomized, placebo- and haloperidol-controlled ziprasidone trials were a...
متن کاملPatient-reported tolerability of adverse events in phase 1 trials
BACKGROUND Phase I experts recommend revisiting dose-limiting toxicity (DLT) definition to include chronic and cumulative toxicities induced by new molecularly targeted therapies. Patient's assessment of late toxicities' tolerability is, however, unknown. MATERIALS AND METHODS A prospective survey on adverse events (AEs) tolerability on 23 National Cancer InstituteCommon Terminology Criteria ...
متن کاملVaccine adverse events reported in New Zealand 1990-5.
AIM New Zealand monitors vaccine safety through vaccinator reports of adverse events following immunisation. The rate of reporting for the commonly used vaccines during 1990-5 are presented. During this time new vaccines were added to the immunisation schedule, enabling comparison of reporting rates. METHOD The number of events were obtained from the CARM database and a rate calculated based ...
متن کاملAdverse events reported following live, cold-adapted, intranasal influenza vaccine.
CONTEXT In June 2003, the US Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20 228 vaccinees, clinical trials were not of sufficient size to detect rare adverse events reliably. OBJECTIVE To identify adverse events reported following LAIV...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: YAKUGAKU ZASSHI
سال: 2016
ISSN: 0031-6903,1347-5231
DOI: 10.1248/yakushi.15-00224-5